These results offer a strong rationale for human clinical trials testing DF-003 as an ALPK1 inhibitor with the potential to serve as a precision-targeted drug for treating the progressive manifestations of ROSAH syndrome. This evidence concerns the gene ALPK1 and retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome.